AbbVie (ABBV) Cash from Financing Activities (2012 - 2026)
AbbVie (ABBV) reported Cash from Financing Activities of $919.0 million for Q1 2026, up 173.05% year-over-year from $336.6 million in Q1 2025, and up 122.06% on a QoQ basis from -$4.2 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Cash from Financing Activities data on file, last reported at $919.0 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 173.05% year-over-year to $919.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.5 billion (up 38.99% YoY) and the FY2025 annual result came in at -$12.7 billion, down 144.18% from the prior year.
- Cash from Financing Activities rose to $919.0 million in Q1 2026 per ABBV's latest filing, from -$4.2 billion in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $10.8 billion in Q1 2024 and bottomed at -$9.6 billion in Q4 2022.
- The 5-year median for Cash from Financing Activities is -$4.2 billion (2025), against an average of -$3.5 billion.
- The widest annual swing landed in 2022, when Cash from Financing Activities tumbled 119.66%; it then surged 274.73% in 2024.
- Tracing ABBV's Cash from Financing Activities over 5 years: stood at -$9.6 billion in 2022, then jumped by 53.82% to -$4.4 billion in 2023, then sank by 54.21% to -$6.9 billion in 2024, then jumped by 39.28% to -$4.2 billion in 2025, then surged by 122.06% to $919.0 million in 2026.
- Per Business Quant, the three latest ABBV Cash from Financing Activities figures stand at $919.0 million (Q1 2026), -$4.2 billion (Q4 2025), and -$4.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -3.47 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 530.00 Mn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 919.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -1.56 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 919.00 Mn |
| Mar 31, 2026 | 919.00 Mn |
| Dec 31, 2025 | -4.17 Bn |
| Dec 31, 2025 | -4.17 Bn |
| Sep 30, 2025 | -4.59 Bn |
| Sep 30, 2025 | -4.59 Bn |
| Jun 30, 2025 | -2.71 Bn |
| Jun 30, 2025 | -2.71 Bn |
| Mar 31, 2025 | -1.26 Bn |
| Mar 31, 2025 | -1.26 Bn |
| Dec 31, 2024 | -6.86 Bn |
| Dec 31, 2024 | -6.86 Bn |
| Sep 30, 2024 | -3.07 Bn |
| Sep 30, 2024 | -3.07 Bn |
| Jun 30, 2024 | -6.10 Bn |
| Jun 30, 2024 | -6.10 Bn |
| Mar 31, 2024 | 10.82 Bn |
| Mar 31, 2024 | 10.82 Bn |
| Dec 31, 2023 | -4.45 Bn |
| Dec 31, 2023 | -4.45 Bn |
| Sep 30, 2023 | -2.66 Bn |
| Sep 30, 2023 | -2.66 Bn |
| Jun 30, 2023 | -3.92 Bn |
| Jun 30, 2023 | -3.92 Bn |
| Mar 31, 2023 | -6.19 Bn |
| Mar 31, 2023 | -6.19 Bn |
| Dec 31, 2022 | -9.63 Bn |
| Dec 31, 2022 | -9.63 Bn |
| Sep 30, 2022 | -5.52 Bn |
| Sep 30, 2022 | -5.52 Bn |
| Jun 30, 2022 | -2.68 Bn |
| Jun 30, 2022 | -2.68 Bn |
| Mar 31, 2022 | -6.97 Bn |
| Mar 31, 2022 | -6.97 Bn |
| Dec 31, 2021 | -6.34 Bn |
| Dec 31, 2021 | -6.34 Bn |
| Sep 30, 2021 | -3.64 Bn |
| Sep 30, 2021 | -3.64 Bn |
| Jun 30, 2021 | -5.88 Bn |
| Jun 30, 2021 | -5.88 Bn |
| Mar 31, 2021 | -3.17 Bn |
| Mar 31, 2021 | -3.17 Bn |
| Dec 31, 2020 | -3.70 Bn |
| Dec 31, 2020 | -3.70 Bn |
| Sep 30, 2020 | -2.81 Bn |
| Sep 30, 2020 | -2.81 Bn |
| Jun 30, 2020 | -2.57 Bn |
| Jun 30, 2020 | -2.57 Bn |
| Mar 31, 2020 | -2.42 Bn |
| Mar 31, 2020 | -2.42 Bn |
| Dec 31, 2019 | 26.60 Bn |
| Dec 31, 2019 | 26.60 Bn |
| Sep 30, 2019 | -441.00 Mn |
| Sep 30, 2019 | -441.00 Mn |
| Jun 30, 2019 | -2.07 Bn |
| Jun 30, 2019 | -2.07 Bn |
| Mar 31, 2019 | -5.38 Bn |
| Mar 31, 2019 | -5.38 Bn |
| Dec 31, 2018 | -3.83 Bn |
| Dec 31, 2018 | -3.83 Bn |
| Sep 30, 2018 | 916.00 Mn |
| Sep 30, 2018 | 916.00 Mn |
| Jun 30, 2018 | -8.98 Bn |
| Jun 30, 2018 | -8.98 Bn |
| Mar 31, 2018 | -2.51 Bn |
| Mar 31, 2018 | -2.51 Bn |
| Dec 31, 2017 | -1.93 Bn |
| Dec 31, 2017 | -1.93 Bn |
| Sep 30, 2017 | -14.00 Mn |
| Sep 30, 2017 | -14.00 Mn |
| Jun 30, 2017 | -13.00 Mn |
| Jun 30, 2017 | -13.00 Mn |
| Mar 31, 2017 | -1.79 Bn |
| Mar 31, 2017 | -1.79 Bn |
| Dec 31, 2016 | -2.50 Bn |
| Dec 31, 2016 | -2.50 Bn |
| Sep 30, 2016 | -1.37 Bn |
| Sep 30, 2016 | -1.37 Bn |
| Jun 30, 2016 | 1.16 Bn |
| Jun 30, 2016 | 1.16 Bn |
| Mar 31, 2016 | -1.22 Bn |
| Mar 31, 2016 | -1.22 Bn |
| Dec 31, 2015 | -2.43 Bn |
| Dec 31, 2015 | -2.43 Bn |
| Sep 30, 2015 | -1.06 Bn |
| Sep 30, 2015 | -1.06 Bn |
| Jun 30, 2015 | 10.17 Bn |
| Jun 30, 2015 | 10.17 Bn |
| Mar 31, 2015 | -930.00 Mn |
| Mar 31, 2015 | -930.00 Mn |
| Dec 31, 2014 | -882.00 Mn |
| Dec 31, 2014 | -882.00 Mn |
| Sep 30, 2014 | -719.00 Mn |
| Sep 30, 2014 | -719.00 Mn |
| Jun 30, 2014 | -415.00 Mn |
| Jun 30, 2014 | -415.00 Mn |
| Mar 31, 2014 | -1.28 Bn |
| Mar 31, 2014 | -1.28 Bn |
| Dec 31, 2013 | -747.00 Mn |
| Dec 31, 2013 | -747.00 Mn |
| Sep 30, 2013 | -613.00 Mn |
| Sep 30, 2013 | -613.00 Mn |
| Jun 30, 2013 | -500.00 Mn |
| Jun 30, 2013 | -500.00 Mn |
| Mar 31, 2013 | -1.58 Bn |
| Mar 31, 2013 | -1.58 Bn |
| Dec 31, 2012 | 2.39 Bn |
| Dec 31, 2012 | 2.39 Bn |
| Sep 30, 2012 | 2.24 Bn |
| Sep 30, 2012 | 2.24 Bn |
| Jun 30, 2012 | -1.33 Bn |
| Jun 30, 2012 | -1.33 Bn |
| Mar 31, 2012 | -1.38 Bn |
| Mar 31, 2012 | -1.38 Bn |